Acyclic Nitrogen Bonded Directly To A -c(=x)- Group, Wherein X Is Chalcogen Patents (Class 544/393)
-
Publication number: 20110152245Abstract: The invention relates to compounds of formula wherein R, R1, R2, X, and Y are as defined herein and to a pharmaceutically suitable acid addition salt thereof. Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.Type: ApplicationFiled: December 16, 2010Publication date: June 23, 2011Inventors: Katrin Groebke Zbinden, Roger Norcross, Philippe Pflieger
-
Patent number: 7964605Abstract: The present invention relates to a novel piperazine derivative or pharmaceutically acceptable salt thereof, a process for preparing the same, a pharmaceutical composition for treating central nervous system diseases comprising an effective amount of the piperazine compound and a method of treating central nervous system (CNS) disorder such as psychosis in a mammal.Type: GrantFiled: May 29, 2008Date of Patent: June 21, 2011Assignee: SK Holdings Co., Ltd.Inventors: Yonggil Kim, Kiho Lee, Nahmryune Cho, Jin Uk Yoo, Joon Heo, Choonho Ryu, Seonmin Dong, Man-Young Cha, Jong Gil Choi, Yunhee Kim, Mi Kyung Ji
-
Publication number: 20110124657Abstract: The present invention relates to compounds having pharmacological activity towards the 5-HT7 receptor; to a method for identifying them as 5-HT7 ligands, especially as agonists, by using a pharmacophore and a descriptor's profile filter; to pharmaceutical compositions comprising them; and to their use in therapy, in particular for the treatment and or prophylaxis of a disease in which 5-HT7 is involved, such as CNS disorders.Type: ApplicationFiled: July 30, 2009Publication date: May 26, 2011Applicant: LABORATORIOS DEL DR. ESTEVE, S.A.Inventors: Rosalia Pascual-Ramon, H. Helmut Buschmann
-
Publication number: 20110117214Abstract: The present invention relates to new cyclohexyl urea modulators of D2 receptors and/or modulators of D3 receptors, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: November 15, 2010Publication date: May 19, 2011Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Ronald C. Newbold, Chengzhi Zhang
-
Patent number: 7943621Abstract: The present invention relates to novel monohydrochloride, dihydrochloride, monohydrobromide, maleate and methanesulphonate salts of trans 4-{2-[4-(2,3-dichlorophenyl)-piperazine-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine and/or their hydrates and/or solvates. Moreover, the invention relates to the process for preparing the salts and their hydrates and/or solvates, to their use in the treatment and/or prevention of conditions which require modulation of dopamine receptor and to pharmaceutical compositions containing them.Type: GrantFiled: May 9, 2008Date of Patent: May 17, 2011Assignee: Richter Gedeon Nyrt.Inventors: Laszlo Czibula, Ferenc Sebok, Istvan Greiner, Gyorgy Domany, Eva Againe Csongor
-
Publication number: 20110077247Abstract: New histone deacetylase inhibitors according to the general formula (I) wherein: Q is a bond, CH2, CH—NR3R4, NR5 or oxygen, X is CH or nitrogen, Y is a bond, CH2, oxygen or NR6, Z is CH or nitrogen, R1, R2 are, independently, hydrogen, halogen, C1-C6 alkyl or C1-C6 haloalkyl, R11, R12 are, independently, hydrogen or C1-C6 alkyl, and R3, R4, R5 and R6 are as further defined in the specification.Type: ApplicationFiled: December 7, 2010Publication date: March 31, 2011Applicant: DAC S.r.I.Inventors: Antonello Mai, Saverio Minucci, Florian Thaler, Gilles Pain, Andrea Colombo, Stefania Gagliardi, Pier Giuseppe Pelicci, Marco Ballarini, Gaetano Gargiulo, Silvio Massa
-
Publication number: 20110071066Abstract: The present invention relates to the use of selected metal complex compounds and ligands as oxidation catalysts as well as to a process for removing stains and soil on textiles and hard surfaces. The metal complex compounds have hydrazide ligands preferably with electron withdrawing groups in the phenyl ring adjacent to the acyl group. Further aspects of the invention are formulations comprising such metal complex compounds, novel metal complex compounds and novel ligands.Type: ApplicationFiled: March 30, 2009Publication date: March 24, 2011Applicant: BASF SEInventors: Barbara Wagner, Hauke Rohwer, Marie-Josee Dubs, Menno Hazenkamp, Kai Eichin, Albert Schneider
-
Publication number: 20110039802Abstract: The present invention provides a pharmaceutical composition for use as an NPY Y5 receptor antagonist comprising a compound of the formula (I): wherein R1 is lower alkyl, cycloalkyl or the like, R2 is hydrogen, lower alkyl or the like, n is 1 or 2, X is lower alkylone, lower alkenylene, arylene, cycloalkylene or the like, Y is CONR7, CSNR7, NR7CO, NR7CS or the like, Z is lower alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl or the like and R7 is hydrogen or lower alkyl, prodrug, pharmaceutically acceptable salt or solvate thereofType: ApplicationFiled: July 2, 2010Publication date: February 17, 2011Inventors: Yasuyuki KAWANISHI, Hideyuki TAKENAKA, Kohji HANASAKI, Tetsuo OKADA
-
Publication number: 20110034479Abstract: The present invention is concerned with deuterium-enriched isobutyl and cyclohexylmethyl sulfonamides of formula I and II, and pharmaceutically acceptable salts and methods of use thereof for the treatment of general anxiety disorders, major depressive disorders, attention deficit disorders, attention deficit hyperactivity disorder, Alzheimer's disease, frontotemporal dementia, cognitive impairment associated with age-related dementia, schizophrenia, migraine, sleep disorders, neurodegenerative diseases and obesity.Type: ApplicationFiled: August 9, 2010Publication date: February 10, 2011Inventor: Daljit Singh Dhanoa
-
Publication number: 20110028722Abstract: The present invention relates to novel solvate and crystalline forms of carbamoyl-cyclohexane derivatives and, more particularly, to novel solvate and crystalline forms of trans-1{4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-3,3-dimethyl-urea hydrochloride. Processes for the preparation of these forms, compositions containing these forms, and methods of use thereof are also described.Type: ApplicationFiled: October 5, 2010Publication date: February 3, 2011Inventors: Xiangmin Liao, Haijian Zhu, Andreas Grill
-
Publication number: 20110028491Abstract: It is directed to provide a novel apoptosis inhibitor. Specifically directed is an apoptosis inhibitor containing a biphenylcarboxamide compound represented by the following formula (1) as an active ingredient, wherein R1 represents a hydrogen atom or a lower alkoxy group; R2 represents a hydrogen atom or a lower alkanoyl group; and n represents a number of 2 to 5.Type: ApplicationFiled: January 23, 2009Publication date: February 3, 2011Applicant: NIHON UNIVERSITYInventors: Kumiko Ishige, Yoshihisa Ito, Mioko Hirabayashi
-
Patent number: 7875617Abstract: The invention relates to 3,4-dihydro-2-naphthamide derivatives of formula (I), pharmaceutical compositions containing them and their therapeutic applications as partial agonists or antagonists of the dopamine D3 receptor for the treatment of neuropsychological disorders.Type: GrantFiled: January 20, 2006Date of Patent: January 25, 2011Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Pierre Sokoloff, Catherine Pilon, André Mann, Angéle Schoenfelder, Fabrice Garrido
-
Publication number: 20110003991Abstract: The use of a compound of formula I wherein Y is a single bond, C?O, C?S or S(O)m where m is 0, 1 or 2; the ring is a 6-membered aromatic or is a 5 or 6 membered heteroaromatic ring; Ra, R1, R2, R4 and R8 are specified organic groups; n and p are independently 0-4; or salts or N-oxides thereof or compositions containing them in controlling insects, acarines, nematodes or molluscs. Novel compounds are also provided.Type: ApplicationFiled: September 15, 2010Publication date: January 6, 2011Applicant: SYNGENTA CROP PROTECTION, INC.Inventors: Jérôme CASSAYRE, Peter MAIENFISCH, Fredrik CEDERBAUM, Louis-Pierre MOLLEYRES, Camilla CORSI, Thomas PITTERNA
-
Publication number: 20100324025Abstract: Antibacterial compounds of formula I are provided: As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.Type: ApplicationFiled: September 21, 2009Publication date: December 23, 2010Applicant: University of WashingtonInventors: Niels H. Andersen, Jason Bowman, Alice L. Erwin, Eric A. Harwood, Toni Kline, Khisimuzi E. Mdluli, Simon Ng, Keith B. Pfister, Ribhi Shawar, Allan S. Wagman, Asha Yabannavar
-
Publication number: 20100305123Abstract: This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: Q is a bond, CH2, NR5 or oxygen, X is CH or nitrogen, Y is a bond, CH2, oxygen or NR6, Z is CH or nitrogen, R1, R2 are, independently, hydrogen or C1-C6 alkyl, R3, R4 are, independently, hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl or C1-C6 haloalkoxy, and R5 and R6 are as further defined in the specification, and pharmaceutical acceptable salts thereof.Type: ApplicationFiled: August 26, 2008Publication date: December 2, 2010Applicant: DAC S.R.L.Inventors: Florian Thaler, Mario Varasi, Ciro Mercurio, Saverio Minucci, Andrea Colombo, Stefania Gagliardi
-
Publication number: 20100305088Abstract: This invention is directed to a 3-(amido or sulphamido)-4-(4-substituted-azinyl)benzamide or benzsulphonamide compound as defined herein. The 3-(amido or sulphamido)-(4-substituted-azinyl)benzamide or benzsulphonamide compound is useful as a inhibitor of the chemokine receptor CxCR3, and for preventing or treating a CxCR3 chemokine receptor mediated disease or condition related thereto in a patient in need of such.Type: ApplicationFiled: August 6, 2010Publication date: December 2, 2010Applicant: SANOFI-AVENTISInventors: David S. Thorpe, Martin Smrcina, Dagmar D. Cabel
-
Patent number: 7834008Abstract: The present invention relates to cyclopropyl derivatives of formula (I) and salt thereof. These compounds are NK3 receptor antagonists and may therefore be useful for treatment of diseases where the NK3 receptor is implicated, e.g. psychotic disorders.Type: GrantFiled: August 13, 2004Date of Patent: November 16, 2010Assignee: H. Lundbeck A/SInventors: Jan Kehler, Tore Hansen, Anders Poulsen, Berith Bjørnholm, Thomas Ruhland, Morten Bang Nørgaard, Søren Møller Nielsen
-
Patent number: 7829569Abstract: The present invention relates to novel solvate and crystalline forms of carbamoyl-cyclohexane derivatives and, more particularly, to novel solvate and crystalline forms of trans-1{4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-3,3-dimethyl-urea hydrochloride. Processes for the preparation of these forms, compositions containing these forms, and methods of use thereof are also described.Type: GrantFiled: May 9, 2008Date of Patent: November 9, 2010Assignee: Forest Laboratories Holdings LimitedInventors: Xiangmin Liao, Haijian Zhu, Andreas Grill
-
Publication number: 20100267737Abstract: Dopamine D3 receptor antagonists and partial agonists are known to modulate the reinforcing and drug-seeking effects induced by cocaine and other abused substances. By introducing functionality into the butylamide linking chain of the 4-phenylpiperazine class of ligands, improved D3 receptor affinity and selectivity, as well as water solubility, is achieved. A series of linking-chain derivatives are disclosed wherein functionality such as OH or OAc groups have been introduced into the linking chain. In general, these modifications are well tolerated at D3 receptors and achieve high selectivity over D2 and D4 receptors.Type: ApplicationFiled: June 15, 2007Publication date: October 21, 2010Inventors: Amy Hauck Newman, Peter Grundt, George C. Cyriac, Robert Luedtke, Jianjing Cao
-
Patent number: 7799824Abstract: Quaternary salt compounds of Formula (I) or pharmaceutically acceptable forms thereof, which are CCR2 antagonists and are useful in preventing, treating or ameliorating CCR2 mediated inflammatory syndromes, disorders or diseases in a subject in need thereof.Type: GrantFiled: June 22, 2005Date of Patent: September 21, 2010Assignee: OraPharma, Inc.Inventors: Bharat Lagu, Michael Wachter
-
Publication number: 20100222330Abstract: The present invention relates to substituted sulfonamide compounds of the general formula (I), wherein P is sulfonamide or amide-substituted sulfonic acid, which compounds are potentially useful for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes and/or disorders of the central nervous system.Type: ApplicationFiled: May 17, 2010Publication date: September 2, 2010Applicant: BIOVITRUM ABInventors: Patrizia Caldirola, Gary Johansson, Andrew Mott, Katarina Beierlein, Markus Thor, Lars Tedenborg, Ulf Bremberg, Annika Jenmalm Jensen
-
Patent number: 7786122Abstract: There is provided a series of novel ?-(N-sulfonamido)acetamide compounds of the Formula (I) wherein R, R1, R2 and R3 are defined herein, which are inhibitors of ?-amyloid peptide (?-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by anti-amyloid activity.Type: GrantFiled: October 11, 2007Date of Patent: August 31, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Michael F. Parker, Katharine E. McElhone, Robert A. Mate, Joanne J. Bronson, Yonghua Gai, Carl P. Bergstrom, Lawrence R. Marcin, John E. Macor
-
Publication number: 20100216803Abstract: Provided is a compound which is useful as a therapeutic agent for chronic renal insufficiency and a therapeutic agent for diabetic nephropathy. The present inventors have made extensive studies on an ornithine derivative having an antagonistic action against an EP4 receptor, and as a result, they have found that by introducing cycloalkanediyl at a C terminal of the ornithine part of the compound of the present invention, the physicochemical properties such as solubility, and the like can be improved, thereby giving further preferred properties as a pharmaceutical. Therefore, they have completed the present invention. The compound of the present invention exhibits a good antagonistic action against an EP4 receptor, and thus, it is useful as a therapeutic agent for chronic renal insufficiency and diabetic nephropathy.Type: ApplicationFiled: March 25, 2008Publication date: August 26, 2010Applicant: Astellas Pharma Inc.Inventors: Tatsuya Zenkoh, Eisuke Nozawa, Keisuke Matsuura, Ryushi Seo
-
Patent number: 7767684Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member.Type: GrantFiled: May 12, 2005Date of Patent: August 3, 2010Assignee: Abbott LaboratoriesInventors: Milan Bruncko, Hong Ding, Steven Elmore, Aaron Kunzer, Christopher L. Lynch, William McClellan, Cheol-Min Park, Andrew Petros, Xiaohong Song, Xilu Wang, Noah Tu, Michael Wendt
-
Patent number: 7763616Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.Type: GrantFiled: February 14, 2006Date of Patent: July 27, 2010Assignee: Schering CorporationInventors: Wensheng Yu, Seong Heon Kim, Gopinadhan N. Anilkumar, Stuart B. Rosenblum, Bandarpalle B. Shankar, Brian F. McGuinness, Douglas W. Hobbs, Yuefei Shao
-
Patent number: 7763657Abstract: This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salt thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, and heart disease.Type: GrantFiled: March 15, 2006Date of Patent: July 27, 2010Assignee: Amorepacific CorporationInventors: Hee-Doo Kim, Young-Ger Suh, Hyeung-Geun Park, Uh Taek Oh, Seol Rin Park, Joo Hyun Kim, Mi Jung Jang, Young-Ho Park, Song Seok Shin, Sun-Young Kim, Jin Kwan Kim, Yeon Su Jeong, Ki-Wha Lee, Jin Kyu Choi, Kyung Min Lim, Hyun Ju Koh, Joo Hyun Moh, Sung-Il Kim, Byoung Young Woo
-
Publication number: 20100184750Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.Type: ApplicationFiled: January 18, 2010Publication date: July 22, 2010Applicant: ABBOTT LABORATORIESInventors: Laura A. Hexamer, Hong Ding, Steven W. Elmore, Aaron R. Kunzer, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Michael D. Wendt
-
Publication number: 20100184776Abstract: The invention relates to a DGAT inhibitor of formula (I) including any stereochemically isomeric form thereof, wherein A represents CH or N; X represents O or NRx; the dotted line represents an optional bond in case A represents a carbon atom; Y represents a direct bond; —NRx—C(?O)—; —C(?O)—NRx—; —NRx—C(?O)—Z—; —NRx—C(?O)—Z—NRy—; —NRx—C(?O)—Z—NRy—C(?O)—; —NRx—C(?O)—Z—NRy—C(?O)—O—; —NRx—C(?O)—Z—O—; —NRx—C(?O)—Z—O—C(?O)—; —NRx—C(?O)—Z—C(?O)—; —NRx—C(?O)—Z—C(?O)—O—; —NRx—C(?O)—O—Z—C(?O)—; —NRx—C(?O)—O—Z—C(?O)—O—; —NRx—C(?O)—O—Z—O—C(?O)—; —NRx—C(?O)—Z—C(?O)—NRy—; —NRx—C(?O)—Z—NRy—C(?O)—NRy—; —C(?O)—Z—; —C(?O)—Z—O—; —C(?O)—NRx—Z—; —C(?O)—NRx—Z—O—; —C(?O)—NRx—Z—C(?O)—O—; —C(?O)—NRx—Z—O—C(?O)—; —C(?O)—NRx—O—Z—; —C(?O)—NRx—Z—NRy—; —C(?O)—NRx—Z—NRy—C(?O)—; —C(?O)—NRx—Z—NRy—C(?O)—O—; R1 represents optionally substituted C1-12alkyl; C2-6alkenyl; C2-6alkynyl; C3-6cycloalkyl; aryl1; aryl1C1-6alkyl; Het1; or Het1C1-6alkyl; provided that when Y represents —NRx—C(?O)—Z—; —NRx—C(?O)—Z—NRy; —NRx—C(?O)—Z—C(?O)—NRy—; —C(?O)—Z—;Type: ApplicationFiled: June 5, 2008Publication date: July 22, 2010Applicant: JANSSEN PHARMACEUTICA N.V.Inventors: Jean-Pierre Andre Marc Bongartz, Guy Rosalia Eugeen Van Lommen, Erwin Coesemans, Christophe Francis Robert Nestor Buyck
-
Publication number: 20100174074Abstract: Disclosed herein are benzophenone hybrids with potent anticancer activities and processes for creation of the same.Type: ApplicationFiled: March 26, 2008Publication date: July 8, 2010Inventors: Ahmed Kamal, Bandari Rajendra Prasad
-
Patent number: 7737142Abstract: The present invention relates to new D3 and D2 dopamine receptor subtype preferring ligands of formula (I): wherein R1 and R2 represent independently a substituent selected from hydrogen, alkyl, aryl, cycloalkyl, aroyl, or R1 and R2 may form a heterocyclic ring with the adjacent nitrogen atom; X represents an oxygen or sulphur atom; n is an integer of from 1 to 2, and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof, to the processes for producing the same, to pharmaceutical compositions containing the same and to their use in therapy and/or prevention of a condition which requires modulation of dopamine receptors.Type: GrantFiled: January 20, 2006Date of Patent: June 15, 2010Assignee: Richter Gedeon Vegyeszeti Gyar Rt.Inventors: Eva Againe Csongor, Janos Galambos, Katalin Nogradi, Istvan Vago, Istvan Gyertyan, Bela Kiss, Istvan Laszlovszky, Judit Laszy, Katalin Saghy
-
Publication number: 20100137335Abstract: The present invention relates to metabolites of (thio)carbamoyl cyclohexane derivatives, particularly, metabolites of trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimemylcarbamoyl-cyclohexylamine and pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing the same and to their use in the treatment and/or prevention of a conditions which requires modulation of dopamine receptors.Type: ApplicationFiled: May 15, 2008Publication date: June 3, 2010Inventors: Eva Againe Csongor, Norbert Antal Kirschner, Eva Schmidt, Istvan Gyertyan, Bela Kiss
-
Publication number: 20100068138Abstract: A family of structurally rigid dopamine D3 receptor selective ligands is described. The family of structurally rigid dopamine D3 receptor selective ligands has the formula wherein A is cis or trans —CH?CH—, —C?C—, or cyclohexyl. B is cis or trans —CH?CH— or absent. R1 represents an optionally substituted phenyl group, wherein said substituents are selected from the group consisting of: hydrogen, halogen, amino, nitro, hydroxyl, alkoxy, alkyl, acyl and pyridyl, and said substitution may occur at any of the ortho, meta, or para positions, or R1 represents a heteroaromatic ring. A preferred heteroaromatic ring is indole, quinoxoline, pyridyl, pyrimidyl, or imidazole. R2 and R3 may be independently hydrogen or a halogen, or R2 alone may be C1, C2, or C3 alkoxy, and m is 1 or 2, and n is 0, 1, or 2.Type: ApplicationFiled: September 14, 2009Publication date: March 18, 2010Inventors: Amy Newman, Peter Grundt, Robert R. Luedtke
-
Patent number: 7671058Abstract: A compound represented by the following formula (I) or a salt thereof: wherein R1, R2, R3 and R4 represent hydrogen atom, a halogen atom, cyano group, nitro group, a C1-4 alkyl group, a halogenated C1-4 alkyl group or a C1-4 alkoxy group, R5 represents a halogen atom, cyano group, a C1-4 alkyl group, a halogenated C1-4 alkyl group or a C1-4 alkoxy group, R6 represents a C5-7 cycloalkyl group, a substituted C5-7 cycloalkyl group, a 5 to 7-membered completely saturated heterocyclic group or a substituted 5 to 7-membered completely saturated heterocyclic group, X represents a single bond, oxygen atom, sulfur atom, NR7, —O—CH2— or —N(R8)—CH2—, R7 represents hydrogen atom or a C1-4 alkyl group, or R7 may combine with a substituent of R6 to represent a single bond, methylene group or ethylene group, R8 represents hydrogen atom, a C1-4 alkyl group or a C7-12 aralkyl group, which is useful as an active ingredient of a medicament for prophylactic and/or therapeutic treatment of diseases caused by an activation ofType: GrantFiled: June 19, 2007Date of Patent: March 2, 2010Assignee: Institute of Medicinal Molecular Design, Inc.Inventors: Ryukou Tokuyama, Toshifumi Wakamatsu, Tatsurou Ichige, Susumu Muto, Akiko Itai
-
Publication number: 20100016334Abstract: The present invention relates to stable and bioavailable immediate release formulations comprising dopamine receptor ligands. Methods of treating various disorders by administering the formulations are also described.Type: ApplicationFiled: July 16, 2009Publication date: January 21, 2010Inventors: Ranajoy SARKAR, Mahendra G. DEDHIYA, Anil CHHETTRY
-
Publication number: 20100010004Abstract: This invention comprises the novel compounds of formula (I) wherein n, R1, R2, R3, R4, Q, X, Y, Z and have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositions containing them and their use as a medicine.Type: ApplicationFiled: September 16, 2009Publication date: January 14, 2010Inventors: Kristof VAN EMELEN, Marc Gustaaf Celine VERDONCK, Sven Franciscus Anna VAN BRANDT, Patrick René ANGIBAUD, Lieven MEERPOEL, Alexey Borisovich DYATKIN
-
Patent number: 7629493Abstract: The invention relates to a process for the crystallization of the compounds of the formula (I) or acid-addition salts thereof, in which R1, R2 and R3 have the meaning indicated in Claim 1.Type: GrantFiled: April 10, 2004Date of Patent: December 8, 2009Assignee: Merck Patent GmbHInventors: Michael Kirschbaum, Ekkehard Bartmann, Dieter Bensinger, Alexander Haas, Ricky Lippert
-
Publication number: 20090285849Abstract: Novel immune potentiators, novel vaccine adjuvants, novel compounds and pharmaceutical compositions, as well as novel methods for treating viral infections, including HCV, by administering the compounds and compositions, and novel methods for modulating the immune response by administering the compounds and/or compositions.Type: ApplicationFiled: February 26, 2009Publication date: November 19, 2009Inventors: Paul A. Barsanti, Nathan Brammeier, Anthony Diebes, Liana Marie Lagniton, Simon NG, Zhi Jie Ni, Keith B. Pfister, Casey Philbin, Nicholas Valiante, Allan S. Wagman, Weibo Wang, Amy J. Weiner
-
Publication number: 20090247509Abstract: The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders.Type: ApplicationFiled: April 17, 2009Publication date: October 1, 2009Applicant: AVENTIS PHARMACEUTICALS INC.Inventors: James A. Hendrix, Horst Hemmerle, Matthias Urmann, Gregory M. Shutske, Joseph T. Strupczewski, Kenneth J. Bordeau, John G. Jurcak, Thaddeus R. Nieduzak, Sharon A. Jackson, Paul Angell, James P. Carey, George Lee, David Fink, Jean-Francois Sabuco, Yulin Chiang, Nicola Collar
-
Patent number: 7579467Abstract: The present invention relates to novel amides and a process for preparing these amides.Type: GrantFiled: August 28, 2007Date of Patent: August 25, 2009Assignee: Novartis AGInventors: Olivier Loiseleur, Daniel Kaufmann, Stephan Abel, Hans Michael Bürger, Mark Meisenbach, Beat Schmitz, Gottfried Sedelmeier
-
Publication number: 20090181943Abstract: This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula compounds of the Formula (I) and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein groups L, M, X and Y are as defined herein.Type: ApplicationFiled: April 9, 2008Publication date: July 16, 2009Applicant: METHYLGENE INC.Inventors: Pierre Tessier, Silvana Leit, David Smil, Robert Deziel, Alain Ajamian, Yves Andre Chantigny, Celia Dominguez
-
Publication number: 20090170836Abstract: This invention comprises the novel compounds of formula (I) wherein n, t, R1, R2, R3, R4, L, Q, X, Y, Z and have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositions containing them and their use as a medicine.Type: ApplicationFiled: February 18, 2009Publication date: July 2, 2009Inventors: Patrick Rene Angibaud, Isabelle Noelle Constance Pilatte, Sven Franciscus Anna Van Brandt, Bruno Roux, Peter Ten Holte, Marc Gustaaf Celine Verdonck, Lieven Meerpoel, Alexey Borisovich Dyatkin
-
Patent number: 7547701Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.Type: GrantFiled: September 17, 2004Date of Patent: June 16, 2009Assignee: Virobay, Inc.Inventors: John O. Link, Craig J. Mossman, Soon H. Woo, Sheila M. Zipfel
-
Patent number: 7544716Abstract: This invention relates to tetrahydro-naphthalene derivatives of formula (I) in which the variable groups are as defined in the specification and claims, and tautomeric and stereoisomeric forms and salts thereof which are useful as active ingredients of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have an excellent activity as VR1 antagonists and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD. The compounds, pharmaceutical compositions containing them, and methods of treatment using them are disclosed and claimed.Type: GrantFiled: November 28, 2003Date of Patent: June 9, 2009Assignee: Xention LimitedInventors: Masaomi Tajimi, Toshio Kokubo, Masahiro Shiroo, Yasuhiro Tsukimi, Takeshi Yura, Klaus Urbahns, Noriyuki Yamamoto, Muneto Mogi, Hiroshi Fujishima, Tsutomu Masuda, Nagahiro Yoshida, Toshiya Moriwaki
-
Publication number: 20090143394Abstract: Compositions and methods for treatment and prevention of disorders and conditions characterized by reduced TGF-? signaling are described.Type: ApplicationFiled: October 10, 2008Publication date: June 4, 2009Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Anton Wyss-Coray, Mary J. Tanga
-
Publication number: 20090105237Abstract: A method of conferring a cooling effect on the skin or mucous membranes by applying thereto at least one compound of the Formula I: (a) wherein B is selected from H, CH3, C2H5, OCH3, OC2H5; and OH; and (b) wherein A is a moiety of the formula —CO-D, wherein D is selected from the following moieties: (i) —NR1R2, wherein R1 and R2 are independently selected from H and C1-C8 straight or branched-chain aliphatic, alkoxyalkyl, hydroxyalkyl, araliphatic and cycloalkyl groups, or R1 and R2 together with the nitrogen atom to which they are attached form part of an optionally-substituted, five- or six-membered heterocyclic ring; (ii) —NHCH2COOCH2CH3, —NHCH2CONH2, —NHCH2CH2OCH3, —NHCH2CH2OH, —NHCH2CH(OH)CH2OH and (iii) a moiety selected from the group consisting of: The compounds are useful for providing cooling effects in a variety of products, such as foodstuffs, confectionery, tobacco products, beverages, cosmetics, dentifrices, medicinal preparations, mouthwashes and toiletries.Type: ApplicationFiled: May 24, 2006Publication date: April 23, 2009Inventors: Karen Ann Bell, Stefan Michael Furrer, Christophe C. Galopin, Pablo Victor Krawec, Jay Patrick Slack
-
Publication number: 20090099199Abstract: The invention relates to compound of the formula I wherein the substituents are as defined in the specification; in free base form or in acid addition salt form; to its preparation, to its use as medicament and to medicaments comprising it.Type: ApplicationFiled: October 15, 2008Publication date: April 16, 2009Inventors: Joachim Nozulak, David Orain, Simona Cotesta
-
Patent number: 7517885Abstract: The present invention relates to substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds of Formula (I) and pharmaceutically acceptable forms thereof, as ?1a/?1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as methods of treatment.Type: GrantFiled: June 14, 2006Date of Patent: April 14, 2009Assignee: Janssen Pharmaceutica N.V.Inventors: George Chiu, Peter J. Connolly, Jessica J. Liu, Steven A. Middleton, Virginia L. Pulito, Shengjian Li
-
Patent number: 7488730Abstract: A series of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides was prepared and their affinity for serotonin 5-HT7, 5-HT1A, and 5-HT2A receptors was measured using in vitro binding assays. In relation to 5-HT7 receptor affinity, receptor binding studies indicated that: (i) the optimal alkyl chain length was five methylenes; (ii) an unsubstituted 1,2,3,4-tetrahydronaphthalenyl nucleus was selected for further substitutions; and (iii) the substitution pattern of the aryl ring linked to the piperazine ring played a significant role. Several compound with high affinity for 5-HT7 receptors were identified.Type: GrantFiled: November 18, 2005Date of Patent: February 10, 2009Assignee: Universita Degli Studi Di BariInventors: Marcello Leopoldo, Francesco Berardi, Nicola Antonio Colabufo, Marialessandra Contino, Enza Lacivita, Mauro Niso, Roberto Perrone, Vincenzo Tortorella
-
Patent number: 7488731Abstract: The invention relates to 5-HT receptor agonists or antagonists. Novel arylpiperazinyl sulfonamide compounds represented by Formula I, and synthesis and uses thereof for treating diseases including those mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as generalized anxiety disorder, ADD/ADHD, neural injury, stroke, and migraine. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.Type: GrantFiled: July 24, 2007Date of Patent: February 10, 2009Assignee: Epix Delaware, Inc.Inventors: Dale S. Dhanoa, Dongli Chen, Oren Becker, Silvia Noiman, Srinivasa R. Cheruku, Yael Marantz, Anurag Sharadendu, Sharon Shacham, Alexander Heifetz, Pradyumna Mohanty, Boaz Inbal, Merav Fichman, Raphael Nudelman, Shay Bar-Haim
-
Publication number: 20090023750Abstract: The present invention relates to novel monohydrochloride, dihydrochloride, monohydrobromide, maleate and methanesulphonate salts of trans 4-{2-[4-(2,3-dichlorophenyl)-piperazine-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine and/or their hydrates and/or solvates. Moreover, the invention relates to the process for preparing the salts and their hydrates and/or solvates, to their use in the treatment and/or prevention of conditions which require modulation of dopamine receptor and to pharmaceutical compositions containing them.Type: ApplicationFiled: May 9, 2008Publication date: January 22, 2009Applicant: RICHTER GEDEON NYRT.Inventors: Laszlo Czibula, Ferenc Sebok, Istvan Greiner, Gyorgy Domany